Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo2 Clear all
Completed Not applicable Interventional Results available

Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper

NCT02737826
View directory record Official record
Conditions
Chronic Pain, Opioid Pain Medication
Interventions
Buprenorphine Initiation - Phase I, Gabapentin + Buprenorphine - Phase II, Placebo + Buprenorphine - Phase II, Buprenorphine taper - Phase II
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer

NCT02200614
View directory record Official record
Conditions
Prostate Cancer Non-Metastatic, Castration-Resistant
Interventions
Darolutamide (Nubeqa, BAY1841788), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
55
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

NCT05988710
View directory record Official record
Conditions
Analgesia, Abuse Opioids, Pain
Interventions
Buccal Buprenorphine 300 mcg, Buccal Buprenorphine 600 mcg, Buccal Buprenorphine 900 mcg, Buccal Placebo, Oral Placebo, Oral immediate-release oxycodone 10mg, Buccal Buprenorphine 450mcg
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Staccato Loxapine Pulmonary Safety in Healthy Volunteers

NCT00789360
View directory record Official record
Conditions
Healthy
Interventions
Inhaled Placebo, Inhaled Loxapine
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Dartmouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 20, 2026, 8:51 AM EDT
Terminated Phase 3 Interventional Results available

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00449150
View directory record Official record
Conditions
Benign Prostatic Hypertrophy
Interventions
Cetrorelix 78 mg + 78 mg, Cetrorelix 78 mg + 52 mg, Placebo
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
50 Years and older · Male only
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
46
States / cities
Huntsville, Alabama • Fort Smith, Arkansas • Laguna Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2018 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional

Intramuscular Ketamine for Suicidal Ideation

NCT05105061
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine (Ketalar), Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 20, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD

NCT00539188
View directory record Official record
Conditions
Borderline Personality Disorder, Self-Injurious Behavior
Interventions
N-Acetylcysteine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Prevention of Severe Postpartum Hypertension

NCT02450773
View directory record Official record
Conditions
Hypertension
Interventions
Furosemide, Potassium chloride, Placebo #1, Placebo #2
Drug
Lead sponsor
Indiana University
Other
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Onset of Action of a Fast Release Aspirin

NCT01420094
View directory record Official record
Conditions
Healthy Subjects
Interventions
Acetylsalicyclic acid (Fast release Aspirin, BAY1019036), Acetaminophen (Tylenol extra strength), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
510 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 20, 2026, 8:51 AM EDT
Withdrawn Phase 2 Interventional

Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

NCT01471652
View directory record Official record
Conditions
Chronic Fatigue Syndrome
Interventions
Nutraceutical supplements, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
25 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Coenzyme Q10 in Adult-Onset Ataxia

NCT00957216
View directory record Official record
Conditions
Sporadic Ataxia
Interventions
Placebo (sugar pill), Coenzyme Q10
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements

NCT01855373
View directory record Official record
Conditions
Blood Sugar, Endothelial Function
Interventions
PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®, Placebo
Dietary Supplement · Other
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

NCT02229383
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Exenatide, Exenatide matching placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
68
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)

NCT00409539
View directory record Official record
Conditions
Overactive Bladder Syndrome (OABS)
Interventions
Placebo, SMP-986
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
20 Years to 80 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
21
States / cities
Tuscon, Arizona • Atherton, California • San Bernadino, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

NCT03456830
View directory record Official record
Conditions
Enteric Hyperoxaluria
Interventions
ALLN-177, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee

NCT01919164
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Sprifermin, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Lakewood, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 1 Interventional

Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

NCT06265532
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

NCT01511107
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days
Drug
Lead sponsor
Alejandro Hoberman
Other
Eligibility
6 Months to 23 Months
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 20, 2026, 8:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg, Placebo, Biological/Vaccine: BNT162b2 3mcg
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 15 Years
Enrollment
11,837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
90
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 67 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

NCT01847274
View directory record Official record
Conditions
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
Interventions
Active comparator: Niraparib, placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

NCT04641143
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
73
States / cities
Chandler, Arizona • Phoenix, Arizona • Bellflower, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 20, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease

NCT00279825
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
IPX054 200 mg, IPX054 250 mg, CD-LD IR, CD-LD CR, IPX054 200 mg Placebo, IPX054 250 mg Placebo, CD-LD IR Placebo, CD-LD CR Placebo
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Bingham Farms, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 20, 2026, 8:51 AM EDT